Evolutionary fingerprint in rodent PD1 confers weakened activity and enhanced tumor immunity compared to human PD1
Takeya MasubuchiiD, Lin Chen, Nimi MarceliD, George A. WeniD, Christine Caron, Jibin ZhangiD, Yunlong ZhaoiD, Gerald P. MorrisiD, Xu CheniD, Stephen Μ. HedrickiD, Li‐Fan LuiD, Chuan WuiD, Zhengting ZouiD, Jack D. BuiiD, Enfu HuiiD
Abstract
Mechanistic understanding of the immune checkpoint receptor PD1 is largely based on mouse models, but human and mouse PD1 orthologs exhibit only 59.6% identity in amino acid sequences. Here we show that human PD1 is more inhibitory than mouse PD1 due to stronger interactions with the ligands PDL1 and PDL2 and with the effector phosphatase Shp2. A novel motif highly conserved among PD1 orthologs in vertebrates except in rodents is primarily responsible for the differential Shp2 recruitment. Evolutionary analysis suggested that rodent PD1 orthologs uniquely underwent functional relaxation, particularly during the K-Pg boundary. Humanization of the PD1 intracellular domain disrupted the anti-tumor activity of mouse T cells while increasing the magnitude of anti-PD1 response. Together, our study uncovers species-specific features of the PD1 pathway, with implications to PD1 evolution and differential anti-PD(L)1 responses in mouse models and human patients.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 38
- FWCI
- 16.14
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PD1 is transcriptionally regulated by LEF1 in mature T cells
- Granulomatous inflammatory responses are elicited in the liver of PD-1 knockout mice by de novo genome mutagenesis
I. Nagaretnam, A. Yoneshige, … Y. Ishida·bioRxiv·Aug 17, 2023
- Exclusion of PD-1 from the immune synapse: a novel strategy to modulate T cell function
- PD-L1ATTAC mice reveal the potential of targeting PD-L1 expressing cells in cancer therapy
E. Fueyo-Marcos, C. Fustero-Torre, … M. Murga·bioRxiv·Jul 22, 2022
- Interferon-γ driven differentiation of monocytes into PD-L1+ and MHC II+ macrophages and the frequency of Tim-3+ tumor-reactive CD8+ T cells within the tumor microenvironment predict a positive response to anti-PD-1-based therapy in tumor-bearing mice
Jelena Gabrilo, Sylvie Vande Velde, … Oberdan Léo·Cancer Immunology ResearchPeer-reviewed·Aug 28, 2025
- PD-1 Specific 'Blocking' Antibodies That Deplete PD-1+ T Cells Present An Inconvenient Variable In Pre-clinical Immunotherapy Experiments
F. Polesso, M. W. Munks, … A. E. Moran·bioRxiv·Apr 14, 2020